Squarepoint
AXSM icon

Squarepoint’s Axsome Therapeutics AXSM Stock Holding History

Squarepoint’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.8M Buy
154,605
+40,503
+35% +$8.78M 0.04% 429
2026
Q1 		$19.3M Sell
114,102
-40,898
-26% -$7.06M 0.02% 728
2025
Q4 		$28.3M Hold
155,000
– – 0.03% 594
2025
Q3 		$18.8M Sell
155,000
-8,000
-5% -$901K 0.02% 774
2025
Q2 		$17M Buy
163,000
+21,403
+15% +$2.27M 0.02% 844
2025
Q1 		$16.5M Buy
141,597
+52,167
+58% +$5.94M 0.02% 782
2024
Q4 		$7.57M Buy
+89,430
New +$8.22M 0.01% 1316
2024
Q1 		– Sell
-2,550
Closed -$203K – 4011
2023
Q4 		$203K Sell
2,550
-94,211
-97% -$6.3M ﹤0.01% 3586
2023
Q3 		$6.76M Buy
+96,761
New +$7.23M 0.02% 994
2023
Q1 		– Sell
-44,616
Closed -$3.44M – 3226
2022
Q4 		$3.44M Sell
44,616
-87,977
-66% -$5.26M 0.01% 1037
2022
Q3 		$5.92M Buy
132,593
+124,202
+1,480% +$6.21M 0.03% 658
2022
Q2 		$321K Buy
+8,391
New +$265K ﹤0.01% 2262
2021
Q4 		– Sell
-10,730
Closed -$354K – 3157
2021
Q3 		$354K Sell
10,730
-11,273
-51% -$439K ﹤0.01% 2166
2021
Q2 		$1.48M Buy
22,003
+9,474
+76% +$569K 0.01% 1359
2021
Q1 		$709K Buy
+12,529
New +$881K ﹤0.01% 1767
2020
Q2 		– Sell
-18,234
Closed -$1.07M – 2225
2020
Q1 		$1.07M Buy
18,234
+7,937
+77% +$647K 0.03% 694
2019
Q4 		$1.06M Buy
+10,297
New +$416K 0.01% 1290
2019
Q3 		– Sell
-37,706
Closed -$971K – 2338
2019
Q2 		$971K Buy
+37,706
New +$756K 0.01% 1274
2018
Q1 		– Sell
-31,400
Closed -$176K – 1686
2017
Q4 		$176K Sell
31,400
-2,200
-7% -$11.1K ﹤0.01% 1830
2017
Q3 		$186K Buy
+33,600
New +$180K ﹤0.01% 1405

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Squarepoint's AXSM Position: Q2 2026 in Review

Squarepoint increased its Axsome Therapeutics (AXSM) stake by 35% in Q2 2026, buying an estimated $8.78M and bringing the position to 154,605 shares worth $37.8M. The position accounts for 0.04% of the portfolio, ranked #429.

Squarepoint first reported a position in AXSM in Q3 2017 and has held it in 20 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Squarepoint held 154,605 shares of Axsome Therapeutics worth $37.8M as of Q2 2026.
  • Squarepoint bought 40,503 Axsome Therapeutics shares in Q2 2026, an estimated $8.78M.
  • Axsome Therapeutics made up 0.04% of Squarepoint's portfolio in Q2 2026, its #429 holding.
  • Squarepoint first reported a position in Axsome Therapeutics in Q3 2017 and has held it in 20 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.